Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Priority Review Politics: With Two Pending DMD Products, FDA Still Faces Community Anxiety

Executive Summary

Duchenne muscular dystrophy advocates want updates on Sarepta's eteplirsen application; priority review for Marathon's deflazacort illuminates FDA's many considerations in agency’s ongoing effort to approve therapies for DMD.

Advertisement

Related Content

Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture
Keeping Track: Janssen Gets A Breakthrough Therapy Status, FDA Awards Two Orphan Drug Designations, Portola Lands A CRL
You Just Have To Wait: FDA Can't Hurry PDUFA VI Guidances
Marathon Looking To Go The Distance In DMD
FDA Finds Fault With Third Duchenne Muscular Dystrophy Drug Filing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register